Stiris Research Inc. Awarded First-in-Human, Phase I clinical trial in Type 1 Diabetes Mellitus

London, ON — July 14, 2020 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced it has been awarded  the full-service project management contract for a Phase I, first-in-human, single-ascending and multiple-ascending dose safety and pharmacokinetic trial of a once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels) in Type 1 Diabetics.

The results of this study will help define the safety profile of this therapeutic and begin to highlight the effect during hypoglycemia in T1D patients.

“We’re really excited about this project.  The Sponsor’s team is great, and we will be collaborating with a fantastic local SMO. We know that kicking off this study during a pandemic will have its challenges, but we’re confident we have the right team in place to achieve all the study milestones,”  said Urszula Bartlomiejska, Project Management, Stiris Research, Inc.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.